Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06679101 · ClinicalTrials.gov registry record · Phase 3
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
A Phase 3 study of Multiple Myeloma and Newly Diagnosed Multiple Myeloma, sponsored by GlaxoSmithKline.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 520
- Enrollment target
- 20
- Study locations
NCT06679101 is a Phase 3 study of Multiple Myeloma and Newly Diagnosed Multiple Myeloma that is actively recruiting participants, run by GlaxoSmithKline. The registered enrollment target is 520 participants, roughly in line with the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target. The trial reports 20 study locations across 15 states.
The verdict
NCT06679101, a Phase 3 study of Multiple Myeloma and Newly Diagnosed Multiple Myeloma, is actively recruiting participants, sponsored by GlaxoSmithKline.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 520 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this Phase 3 study is to evaluate if BRd prolongs progression free survival (PFS) and/or improves minimal residual disease (MRD) negative status compared with DRd in participants with TI-NDMM.
Conditions Studied
Interventions
- DRUG Belantamab mafodotin
- DRUG Dexamethasone
- DRUG Lenalidomide
- DRUG Daratumumab
Study Locations (20)
Florida
- GSK Investigational Site - Englewood
- GSK Investigational Site - Lady Lake
- GSK Investigational Site - Pembroke Pines
- GSK Investigational Site - Saint Augustine
California
- GSK Investigational Site - Beverly Hills
- GSK Investigational Site - Pasadena
North Carolina
- GSK Investigational Site - Charlotte
- GSK Investigational Site - Winston-Salem
Alabama
- GSK Investigational Site - Mobile
Arizona
- GSK Investigational Site - Phoenix
Colorado
- GSK Investigational Site - Aurora
Georgia
- GSK Investigational Site - Atlanta
Maine
- GSK Investigational Site - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 520 participants |
| Start Date | 2024-12-16 |
| Est. Completion | 2031-03-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06679101
The ClinicalTrials.gov registry entry for NCT06679101 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 520 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 4 interventions - of which Belantamab mafodotin is the first listed.
NCT06679101 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Florida, California, North Carolina.
Frequently Asked Questions
What is clinical trial NCT06679101 about?
NCT06679101 is a clinical study titled "A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)". The purpose of this Phase 3 study is to evaluate if BRd prolongs progression free survival (PFS) and/or improves minimal residual disease (MRD) negative status compared with DRd in participants with TI-NDMM.
What is the current status of trial NCT06679101?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 520 participants. The study started on 2024-12-16. Estimated completion is 2031-03-31.
What conditions does trial NCT06679101 study?
This clinical trial studies the following conditions: Multiple Myeloma, Newly Diagnosed Multiple Myeloma.
What interventions are being tested in trial NCT06679101?
The interventions under investigation include: Belantamab mafodotin (DRUG), Dexamethasone (DRUG), Lenalidomide (DRUG), Daratumumab (DRUG).
Who is sponsoring clinical trial NCT06679101?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06679101 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Olanzapine 2.5 vs 5 mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
RECRUITING · Phase 3
-
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 3
-
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
RECRUITING · Phase 3
-
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 3
-
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.